Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women

American Journal of Obstetrics and Gynecology

Volumn 169, Issue 6, 1993, Pages 1536-1539

  Casson, Peter R ^a   Andersen, Richard N ^a   Herrod, Henry G ^a   Stentz, Frankie B ^a   Straughn, Arthur B ^b   Abraham, Guy E ^a   Buster, John E ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b University of Tennessee   (United States)

Author keywords

Dehydroepiandrosterone; dehydroepiandrosterone sulfate; immunosenescence; natural killer cells

Indexed keywords

PRASTERONE SULFATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FLOW CYTOMETRY; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOMODULATION; KILLER CELL; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; DEHYDROEPIANDROSTERONE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; TESTOSTERONE;

EID: 0027144080     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9378(93)90431-H     Document Type: Article

References (23)

1. Decline of adrenal androgen production measured by radioimmunoassay of urinary unconjugated dehydroepiandrosterone
2. Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice
3. Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding
4. Persistence of increased bone resorption and possible role of dehydroepiandrosterone as a bone metabolism determinant in osteoporotic women in late postmenopause
5. Declining adrenal androgens: an association with bone loss in aging women
6. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease
7. Dehy- droepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men
8. Obesity in the dog: role of the adrenal steroid dehydroepiandrosterone (DHEA)
9. Inhibition of tumor development by dehydroepiandrosterone and related steroids
10. Modulation of growth, differentiation and carcinogenesis by dehydroepiandrosterone
11. Abnormal 24-hr mean plasma concentrations of dehydroepiandrosterone sulfate in women with primary operable breast cancer
12. Dehydroepiandrosterone (DHEA) levels in patients with prostatic cancer, heart diseases and under surgery stress
13. Dehydroepiandrosterone enhances IL-2 production and cytotoxic effector function of human T cells
14. Effectiveness of dehydroepiandrosterone in reduction of cryptosporidial activity in immunosuppressed rats
15. Dehydroepiandrosterone (DHEA) and synthetic DHEA analogs are modest inhibitors of HIV-1 HIB replication
16. The cellular and subcellular bases of immunosenescence
17. Definitions, measurements and classifications of the syndromes of obesity
18. Postmenopausal steroid replacement with micronized dehydroepiandrosterone (DHEA): preliminary oral bioavailability and dose proportionality studies
19. Evaluation of lymphocyte phenotype and phytohemagglutinin response in healthy very low birth weight infants
20. Natural killer cell activity in very low birth weight infants
21. Natural killer cells: their role in defenses against disease
22. Evidence for an autocrine/paracrine role for interleukin-6 in bone resorption by giant cells from giant cell tumors of bone
23. Cytokines and estrogen in bone: antiosteoporotic effects